{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002423721,0.002935534,0.006966312,0.0008864314,0.0008151674,0.001963875,0.001488974,0.002415013,0.006063129],"category_scores_gemma":[0.001224399,0.001239746,0.003711309,0.0008674159,0.00192763,0.0022988,0.000607156,0.00555552,0.00131632],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002301407,"about_ca_system_score_gemma":0.002239838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002928834,"about_ca_topic_score_gemma":0.007293588,"domain_scores_codex":[0.9988457,0.0004427224,0.00005096605,0.0002810384,0.00008193243,0.0002976419],"domain_scores_gemma":[0.9988582,0.0001991432,0.0002101876,0.0001079031,0.00006001913,0.0005645496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9510413,0.01729371,0.001405247,0.0005143055,0.002008368,0.00005956375,0.00007610891,0.001092986,0.003448543,0.0001258742,0.001467228,0.02146664],"study_design_scores_gemma":[0.8570209,0.1375127,0.00247833,0.00002522769,0.0008918879,0.00006578738,0.00002627135,0.000424974,0.0005830186,0.00008510052,0.0008602093,0.00002559981],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873152,0.004733432,0.000729646,0.0006918164,0.0005958992,0.00270022,0.001387618,0.0001488413,0.001697357],"genre_scores_gemma":[0.9849583,0.003687061,0.001490385,0.00113533,0.0005520124,0.003046815,0.001998436,0.00007139807,0.00306032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006966312,"threshold_uncertainty_score":0.02028322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0137413535267044,"score_gpt":0.3733654310320024,"score_spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}